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a b s t r a c t
Neurologic involvement is well recognized in Systemic Scleroderma and increasingly
reported in Localized Scleroderma. MRI brain abnormalities are often associated with
symptoms such as seizures or headaches. In some cases they may be clinically silent.
We describe a 23 years old female with head, trunk and limbs scleroderma who developed
Parry–Romberg Syndrome. Brain MRI showed ipsilateral temporal lobe atrophy without any
prominent neurologic symptoms. Neuropsychological examination revealed Mild Cognitive
Impairment. During the 7 years of follow up we have noticed progression of face atrophy but
no progression of brain atrophy. Cognitive functions have been stable. This case highlight
that major MRI brain abnormalities in LS may occur with only subtle clinical manifestation
such as Mild Cognitive Impairment.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Localized Scleroderma (LS) is a group of autoimmune disorders
that affect skin, subcutaneous tissue and sometimes underly-
ing bone. In contrast to Systemic Scleroderma, internal organ
involvement is limited [1]. Many authors consider progressive
hemifacial atrophy called Parry–Romberg Syndrome (PRS) as a
subtype of LS [2].
Neurologic involvement is well recognized in Systemic
Scleroderma. It is also one of the most common systemic
manifestations in LS [1], especially in subtypes that affect
head such as linear scleroderma ‘‘en coup de sabre’’ (LScs) or
Parry–Romberg Syndrome [1,3]. MRI brain abnormalities are* Corresponding author at: Department of Neurology, University Hosp
fax: +48 12 424 86 26.
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0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Soften associated with symptoms including seizures, head-
aches, and clear cognitive impairment. Less is known about
association with Mild Cognitive Impairment.
We described a female with LS involving head, trunk and
limbs, who developed PRS. Patient had ipsilateral focal brain
atrophy with no prominent neurological symptoms. However,
neuropsychological examination showed Mild Cognitive Im-
pairment.
2. Case report
A 23-year-old Caucasian woman with LS was referred to the
Neurology Outpatient Clinic due to asymmetry of the face. Atital, Botaniczna 3, 31-503 Krakow, Poland. Tel.: +48 12 424 86 00;
p. z o.o. All rights reserved.
Fig. 1 – Right temporal lobe atrophy. (A) Frontal MRI T1-weighted frontal image and (B) axial MRI FLAIR image shows right
temporal lobe atrophic changes.
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lesions on the right cheek and neck. Skin biopsy was consisted
with morphea (subtype of LS). New skin changes appeared
bilaterally on the trunk and limbs. Treatment with piascledine
and vitamin E was administered.Fig. 2 – Right facial hemiatrophy in follow up. (A and B) Facial he
affected side and the upper right teeth are crooked (A).Neurologic examination was remarkable only for right
hemifacial atrophy and right mouth deviation. Hyperpigment-
ed, sclerotic lesions were noted on the neck and on the body
(Fig. 1). Brain MRI showed atrophic changes of the right
temporal lobe (Fig. 2) including enlargement of brain sulci,miatrophy on the right. Patient's mouth deviate toward the
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ventricle. There was no signal change noticed on T2 or FLAIR
sequences and no signs of underlying bone involvement. MR
spectroscopy revealed evidence of demyelination – elevated
level of Choline (Cho/Cr), Myo-inositol (MI/Cr), Lactic acid (Lac/
Cr), and Lipid (Lip/Cr).
Neuropsychological examination showed moderate im-
pairment of attention and concentration, low learning abilities
and decline in memory test. The multi domains Mild Cognitive
Impairment was recognized.
In blood sample we detected Anti-U1RNP antibodies.
Rheumatoid factor, anti-Scl70, anti-dsDNA, anti-Jo1, anti-
SM, anti-SS-A, anti-SS-B antibodies were absent. High resolu-
tion CT of the lung was normal and there was no other internal
organ involvement.
We made a diagnosis of Localized Scleroderma and Parry–
Romberg Syndrome with CNS involvement. Treatment with
oral (prednisone 50 mg) and topical (clobetasol propionate)
corticosteroids was started.
During the next 7 years the area of alopecia appeared on
patient's forehead and new sclerotic lesions on the body.
Facial hemiatrophy progressed. Methotrexate was added to
the therapy but after 2 months patient refused such treatment.
Three subsequent MRI performed between 2 and 5 years after
diagnosis of PRS showed no progression of temporal lobe
atrophy. Patient had no neurologic symptoms and did not
notice any worsening in cognitive functioning. Follow-up
neuropsychological examinations showed slight improve-
ment in attention level and memory processes.
3. Discussion
Parry–Romberg Syndrome is a rare disorder characterized by
atrophy of skin, subcutaneous tissue and sometimes bone on
the one side of the face [2]. Neurologic involvement is one of
the most frequent systemic manifestations of the disease. PRS
coexists with other LS subtypes, especially with LScs in up to
53.6% patients [4].
Differential diagnosis between PRS and LScs is often
challenging and some authors consider them to be different
spectrum of the same disease [2]. PRS usually affects entire
side of the face whereas LScs is limited to frontoparietal area
and do not extend below the eyebrow [2,5]. Skin involvement
in LScs includes hard, depressed and hyperpigmented sclerot-
ic lesions with progressive softening over time. Atrophy of skin
and deep underlying tissue is typical for PRS, but it can be also
present in LScs [5].
MRI ﬁndings and neurologic symptoms are similar in
PRS and LScs but are more frequent in the former [2,6].
Patients usually present with epilepsy, headaches and less
frequently pyramidal signs, vision involvement, cranial
nerve palsy, cognitive deterioration and behavioral dis-
orders [1,2].
MRI ﬁndings in Localized Scleroderma include calciﬁca-
tions, white matter lesions and mostly ipsilateral brain
atrophy [7,8]. Blaszczyk et al. compared brain involvement
in PRS and LScs using MRI, angio-MRI and 99mTc-HM-PAO-
SPECT. Brain abnormalities were similar in both diseases [9].
Lesions may progress, remit and relapse, or reach the stablephase. Generally MRI changes do not correlate with clinical
symptoms [7]. Even prominent white matter lesions [7,10] or
CNS tumor [11] can be clinically silent. Sakai et al. presented
47-year-old woman with LScs, who despite extensive white
matter lesions had no neurologic symptoms [12]. They
suggested that this might be explained by interstitial edema,
which cause radiologic abnormalities without changes in
myelin, neurons, or glial cells.
Brain atrophy of different severity was reported in PRS and
other LS types [6,7,13–15]. It can affect the whole hemisphere
or manifest as focal abnormal gyral pattern and blurring of
gray-white matter. Brain atrophy is sometimes associated
with clear cognitive deterioration [13,15] but less is known
about Mild Cognitive Impairment. MRI changes associated
with Mild Cognitive Impairment may be under-recognized in
LS due to publication bias of severe cases. Also, investigation is
often postponed until neurologic symptoms or signs of PRS or
LScs occur and it rarely includes neuropsychological exami-
nation. Our patient had multi domains Mild Cognitive
Impairment that improved in the follow-up. When the patient
was seen ﬁrst time, she was very concerned and worried about
her medical condition. At that time she was also in a very
stressful situation starting her business, working a lot,
sleeping little. This situation might negatively inﬂuence her
cognitive functioning.
When the follow-up neuropsychological examination was
done, we noticed improvement, which can be explain by the
fact that her business was doing well, she hired people
working for her, therefore she had more time to relax. Also her
mood improved. When seen ﬁrst time she expressed general
worries about her future, when seen second time she was
satisﬁed and relaxed.
Since that time she does not complain about any change in
cognitive functioning.
MR brain spectroscopy of our patient showed metabolic
changes consistent with demyelination. In the absence of
pathologic conﬁrmation it is difﬁcult to clarify their etiology.
Few patients with LS had brain biopsy and they showed
evidences of inﬂammation and vascular dysgenesis [16,17].
There are no recommendations which patients with LS
should undergo brain imaging and detailed neurological and
neuropsychological investigation. Our patient had anti-
U1RNP antibodies. Hietarinta et al. studied different types
of antibodies in SS patients and their association with
neurologic ﬁndings. They suggested that subpopulation of
SS patient with anti-U1RNP and those with anti-Scl70
antibodies are more prone to neurologic involvement [18].
Anti-U1RNP were also reported in 3% of LS patients but their
associations with neurologic involvement was not investi-
gated [19].
This case shows that the brain atrophy in LS can manifest
as Mild Cognitive Impairment without other symptoms. Thus,
detailed neurological investigation with brain imaging should
be considered in patients with LS despite no prominent
neurologic symptoms.
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